Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emmaus Life Sciences Inc.

www.emmausmedical.com

Latest From Emmaus Life Sciences Inc.

Emmaus: ‘We Might Stand A Better Chance In Europe Without The EMA’

Emmaus Life Sciences is dusting itself off following the rejection by the European Medicines Agency of the company’s sickle cell disease drug, Xyndari. The company tells the Pink Sheet that it might have better luck in Europe on a country-by-country basis in member states where experts have shown support for its product and where there are many patients with the condition. Not surprisingly, the EMA has defended the system it follows.

Drug Review Approvals

EMA OKs Seven New Drugs But Delivers Another Blow To Emmaus

Seven new drugs have this week moved closer to gaining EU approval following positive recommendations from the European Medicines Agency, but Emmaus’ glutamine product has fared less well and the company is considering another route for getting the drug to sickle cell disease patients in Europe

Europe Drug Review

Emmaus Fumes After EMA Rejects Sickle Cell Drug Again

The US firm has withdrawn its submission to get EU approval for Xyndari. After being turned down by the CHMP, Emmaus may try the decentralized approval procedure instead.

Drug Review Blood & Coagulation Disorders

Second Chance For Roche’s Polivy At CHMP

It's decision time again at the European Medicines Agency and Roche's Polivy and AstraZeneca's Qternmet are among the products up for an opinion on whether they should be approved in the EU.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Gastrointestinal
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Emmaus Life Sciences Inc.
  • Senior Management
  • Yutaka Niihara, MD, CEO
    Kurt Kruger, CFO
    Willis C Lee, COO
    Charles Stark, PharmD, SVP, R&D
  • Contact Info
  • Emmaus Life Sciences Inc.
    Phone: (310) 214-0065
    21250 Hawthorne Blvd.
    Torrance, CA 90503
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register